Date:5/4/2011

ty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company's website at www.cumberlandpharma.com.

About CaldolorCaldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit www.caldolor.com.

About AcetadoteAcetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Cumberland Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
2. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
3. Cumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
4. Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
5. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
6. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
7. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
8. Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors
9. Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
10. Cumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
11. Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010